ImmunoCellular Therapeutics Ltd Company Profile (NASDAQ:IMUC)

About ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)

ImmunoCellular Therapeutics Ltd logoImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IMUC
  • CUSIP: N/A
  • Web:
  • Market Cap: $5.54 million
  • Outstanding Shares: 15,841,000
Average Prices:
  • 52 Week Range: $0.25 - $4.80
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -0.55
  • P/E Growth:
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.83) per share
  • Price / Book: -0.42
  • EBIDTA: ($26,280,000.00)
  • Return on Assets: -189.02%
  • Average Volume: 1.95 million shs.
  • Short Ratio: 0.35

Frequently Asked Questions for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)

What is ImmunoCellular Therapeutics Ltd's stock symbol?

ImmunoCellular Therapeutics Ltd trades on the NASDAQ under the ticker symbol "IMUC."

Who are some of ImmunoCellular Therapeutics Ltd's key competitors?

Who are ImmunoCellular Therapeutics Ltd's key executives?

ImmunoCellular Therapeutics Ltd's management team includes the folowing people:

  • Anthony J. Gringeri Ph.D., President, Chief Executive Officer, Director
  • David E. Fractor, Chief Financial Officer
  • Rahul Singhvi, Lead Independent Director
  • John S. Yu M.D., Director
  • Anthony Gregg Lapointe, Independent Director
  • Mark A. Schlossberg Esq., Independent Director
  • Gary S. Titus, Independent Director

Who owns ImmunoCellular Therapeutics Ltd stock?

ImmunoCellular Therapeutics Ltd's stock is owned by a variety of of retail and institutional investors. Top institutional investors include INTRACOASTAL CAPITAL, LLC (9.99%) and EMPERY ASSET MANAGEMENT, LP (9.99%). View Institutional Ownership Trends for ImmunoCellular Therapeutics Ltd.

How do I buy ImmunoCellular Therapeutics Ltd stock?

Shares of ImmunoCellular Therapeutics Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoCellular Therapeutics Ltd's stock price today?

One share of ImmunoCellular Therapeutics Ltd stock can currently be purchased for approximately $0.35.

MarketBeat Community Rating for ImmunoCellular Therapeutics Ltd (NASDAQ IMUC)
Community Ranking:  1.1 out of 5 (star)
Outperform Votes:  2 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about ImmunoCellular Therapeutics Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/24/2017Maxim GroupReiterated RatingHoldMediumView Rating Details
(Data available from 9/23/2015 forward)


Earnings History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No earnings announcements for this company have been tracked by


Earnings Estimates for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
Current Year EPS Consensus Estimate: $-3.83 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS


Dividend History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
No insider trades for this company have been tracked by


Headline Trends for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
Latest Headlines for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)



ImmunoCellular Therapeutics Ltd (IMUC) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by Staff